Benitec Biopharma Inc
NASDAQ:BNTC
Benitec Biopharma Inc
Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 14 full-time employees. The company went IPO on 2012-07-11. The firm is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The firm's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The firm's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 14 full-time employees. The company went IPO on 2012-07-11. The firm is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The firm's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The firm's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
Program Progress: Benitec advanced its oncology and OPMD gene therapy programs, with a Phase 2 oncology study now active and OPMD clinical entry targeted for early 2019.
Capital Raised: The company raised $8.8 million through an entitlement offer and placement, with strong support from major shareholders.
Financials: Benitec reported a net loss of $8.6 million for Q3 2018, wider than the $3.1 million loss in Q3 2017, mainly due to reduced R&D grant income.
Cash Position: Cash on hand at the end of March 2018 was $10.5 million, down $6.8 million from June 2017.
Regulatory Momentum: Positive feedback from regulators in key countries supports the clinical advancement of BB-301 for OPMD.
Manufacturing Advances: Significant progress in scalable manufacturing for gene therapy products, with clinical-grade material production ramping up.
